SNDX SYNDAX PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, SYNDAX PHARMACEUTICALS INC reported revenue of $72.8M (up 91.8% from a year earlier), net income of −$49.4M and diluted EPS of −$0.55; over the last four quarters revenue was $252M and net income −$221M; for the fiscal year ended December 2025 revenue was $172M, up 627.8% on the year before.

SNDX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $172M, gross profit n/a, operating income −$273M, net income −$285M (margin -165.6%), EPS −$3.29
• Fiscal year ended Dec 2024: revenue $23.7M, gross profit n/a, operating income −$340M, net income −$319M (margin -1346.3%), EPS −$3.72
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$230M, net income −$209M (margin n/a), EPS −$2.98
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$152M, net income −$149M (margin n/a), EPS −$2.46
• Fiscal year ended Dec 2021: revenue $140M, gross profit n/a, operating income $26.2M, net income $24.9M (margin 17.8%), EPS $0.46

SNDX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $72.8M (up 91.8% year over year), net income −$49.4M, EPS −$0.55
• Quarter ended Mar 31, 2026: revenue $64.9M (up 223.6% year over year), net income −$42.7M, EPS −$0.48
• Quarter ended Dec 31, 2025 (from the annual report): revenue $68.5M (up 791.7% year over year), net income −$68.0M, EPS −$0.78
• Quarter ended Sep 30, 2025: revenue $45.9M (up 267.0% year over year), net income −$60.7M, EPS −$0.70
• Quarter ended Jun 30, 2025: revenue $38.0M (up 984.5% year over year), net income −$71.8M, EPS −$0.83
• Quarter ended Mar 31, 2025: revenue $20.0M, net income −$84.8M, EPS −$0.98
• Quarter ended Dec 31, 2024 (from the annual report): revenue $7.68M, net income −$94.2M, EPS −$1.09
• Quarter ended Sep 30, 2024: revenue $12.5M, net income −$84.1M, EPS −$0.98
• Quarter ended Jun 30, 2024: revenue $3.50M, net income −$68.1M, EPS −$0.80
• Quarter ended Mar 31, 2024: revenue $0, net income −$72.4M, EPS −$0.85
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$72.5M, EPS −$1.02
• Quarter ended Sep 30, 2023: revenue $0, net income −$51.1M, EPS −$0.73
• Quarter ended Jun 30, 2023: revenue $0, net income −$44.6M, EPS −$0.64
• Quarter ended Mar 31, 2023: revenue n/a, net income −$41.1M, EPS −$0.59
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$39.2M, EPS −$0.63
• Quarter ended Sep 30, 2022: revenue n/a, net income −$35.4M, EPS −$0.58
• Quarter ended Jun 30, 2022: revenue n/a, net income −$37.6M, EPS −$0.62
• Quarter ended Mar 31, 2022: revenue n/a, net income −$37.2M, EPS −$0.63
• Quarter ended Dec 31, 2021 (from the annual report): revenue $127M, net income $96.2M, EPS $1.84
• Quarter ended Sep 30, 2021: revenue $12.4M, net income −$20.6M, EPS −$0.40

SNDX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$323M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$275M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$161M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$134M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $29.1M, share buybacks n/a

SNDX balance sheet

• Jun 30, 2026: cash $336M, total assets $704M, total liabilities $689M, shareholders' equity $15.1M
• Mar 31, 2026: cash $131M, total assets $473M, total liabilities $431M, shareholders' equity $41.6M
• Dec 31, 2025: cash $135M, total assets $530M, total liabilities $465M, shareholders' equity $64.6M
• Sep 30, 2025: cash $117M, total assets $552M, total liabilities $436M, shareholders' equity $115M
• Jun 30, 2025: cash $109M, total assets $596M, total liabilities $439M, shareholders' equity $157M
• Mar 31, 2025: cash $154M, total assets $641M, total liabilities $426M, shareholders' equity $215M
• Dec 31, 2024: cash $154M, total assets $725M, total liabilities $437M, shareholders' equity $288M
• Sep 30, 2024: cash $133M, total assets $426M, total liabilities $59.4M, shareholders' equity $366M

What is SNDX's revenue?

SYNDAX PHARMACEUTICALS INC reported $252M of revenue over its last four quarters, through June 30, 2026.

Is SNDX profitable?

No. SYNDAX PHARMACEUTICALS INC lost $221M over the last four quarters.

What is SNDX's EPS?

Diluted earnings per share over the last four quarters were −$2.51; −$0.55 in the latest quarter.

SNDX ownership and insider trades · All stocks